<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Esterified estrogen and methyltestosterone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Esterified estrogen and methyltestosterone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Esterified estrogen and methyltestosterone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11534" href="/d/html/11534.html" rel="external">see "Esterified estrogen and methyltestosterone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708758"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Endometrial cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogens have been reported to increase the risk of endometrial carcinoma. Three independent case control studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods. This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade. The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment and on estrogen dose. In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study suggests that cyclic administration of low doses of estrogen may carry less risk than continuous administration; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy. There is no evidence at present that “natural” estrogens are more or less hazardous than “synthetic” estrogens at equiestrogenic doses.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">This combination does not contain a progestin; it is an estrogen/androgen product. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, pulmonary emboli, and deep vein thrombosis in postmenopausal women during 5 years of treatment with oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) relative to placebo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Breast cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The Women's Health Initiative (WHI) study reported increased risks of invasive breast cancer in postmenopausal women during 5 years of treatment with oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone (2.5 mg) relative to placebo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Estrogens should not be used during pregnancy. The use of female sex hormones, both estrogens and progestogens, during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a non-steroidal estrogen, have an increased risk of developing in later life a form of vaginal or cervical cancer that is ordinarily extremely rare. This risk has been estimated as not greater than 4 per 1,000 exposures. Furthermore, a high percentage of such exposed women (from 30 to 90 percent) have been found to have vaginal adenosis, epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether they are precursors of malignancy. Although similar data are not available with the use of other estrogens, it cannot be presumed they would not induce similar changes. Several reports suggest an association between intrauterine exposure to female sex hormones and congenital anomalies, including congenital heart defects and limb reduction defects. One case control study estimated a 4.7-fold increased risk of limb reduction defects in infants exposed in utero to sex hormones (oral contraceptives, hormone withdrawal tests for pregnancy, or attempted treatment for threatened abortion). Some of these exposures were very short and involved only a few days of treatment. The data suggest that the risk of limb reduction defects in exposed fetuses is somewhat less than 1 per 1,000. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well controlled studies that progestogens are effective for these uses. If the combination of estrogens (esterified) and methyltestosterone is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the advisability of pregnancy continuation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks vs benefits:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Other doses of conjugated estrogens with medroxyprogesterone and other combinations of estrogens and progestins were not studied in the WHI and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F167642"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Covaryx;</li>
<li>Covaryx HS;</li>
<li>EEMT;</li>
<li>EEMT HS;</li>
<li>Est Estrogens-Methyltest DS;</li>
<li>Est Estrogens-Methyltest HS</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F167652"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Estrogen and Androgen Combination</li></ul></div>
<div class="block doa drugH1Div" id="F167644"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dosage based on esterified estrogen component: 0.625 to 1.25 mg once daily administered cyclically (3 weeks on, then 1 week off).</p>
<p style="text-indent:-2em;margin-left:2em;">When treating symptoms of menopause, evaluate hormone therapy routinely for appropriate dose, duration, and route of administration for each individual patient based on treatment goals, risk factors, and overall health (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>). Adjust dose based on patient response.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990118"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Edema requiring discontinuation of treatment and diuretic therapy may occur in patients with preexisting kidney impairment.</p></div>
<div class="block doha drugH1Div" id="F50987414"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with severe hepatic impairment. Edema requiring discontinuation of treatment and diuretic therapy may occur in patients with preexisting hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F3182138"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The Beers Criteria recommends avoiding systemic estrogen therapy in postmenopausal patients ≥65 years of age (independent of diagnosis or condition). In older postmenopausal patients already taking systemic estrogens, consider deprescribing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F167624"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">Refer to the Estrogens (Esterified) and the Testosterone monographs.</p></div>
<div class="block coi drugH1Div" id="F167635"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Active thrombophlebitis or thromboembolic disorders; breast cancer (known or suspected), except in appropriately selected patients being treated for metastatic disease; breastfeeding; estrogen-dependent tumor (known or suspected); severe liver damage; history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use, except while in treatment for breast cancer; pregnancy (known or suspected); undiagnosed genital bleeding.</p></div>
<div class="block war drugH1Div" id="F167621"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Based on data from the Women's Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in patients who are postmenopausal using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA). Observational studies noted this risk declines once therapy is discontinued. The risk of breast cancer in patients who are postmenopausal on hormone therapy may depend upon type of estrogen and/or progestogen, dose, timing of therapy initiation, duration of therapy, route of administration, and individual patient characteristics (AACE/ACE [Cobin 2017]; NAMS 2022). Hormone therapy may be associated with increased breast density (NAMS 2022); an increase in abnormal mammogram findings requiring further evaluation has been reported with estrogen alone or in combination with progestogen therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Data related to androgen use (such as methyltestosterone) are limited (Kabat 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Do not use estrogens with or without progestogen to prevent dementia. In the Women's Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women ≥65 years of age taking CE alone or in combination with MPA. It is unknown if these findings apply to younger patients who are postmenopausal. However, hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia (AACE [Goodman 2011]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial cancer: The use of unopposed estrogen in patients with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestogen to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Perform adequate diagnostic measures, including endometrial sampling if indicated, to rule out malignancy in patients who are postmenopausal with undiagnosed abnormal uterine bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer appears to be dose and duration dependent, greatest with use ≥5 years, and may persist following discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestogen in patients with residual endometriosis posthysterectomy. This combination product contains an estrogen and androgen; it does not contain a progestogen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Inherited thrombophilia: Patients with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho 2010; van Vlijmen 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased in patients with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs. Testosterone may also alter serum cholesterol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Available information related to the use of menopausal estrogen or estrogen/progestogen therapy and risk of ovarian cancer is inconsistent. If an association is present, the absolute risk is likely rare and may be influenced by duration of therapy (AACE [Goodman 2011]; ES [Stuenkel 2015]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Polycythemia: Testosterone may increase hemoglobin and hematocrit requiring dose adjustment or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal thrombosis: Discontinue if unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions occur and immediately evaluate for retinal thrombosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Virilization: Androgens may cause irreversible virilization in females, such as deepening of voice, hirsutism, acne, clitoromegaly, or menstrual irregularities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use caution in patients with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Do not use estrogens with or without progestogen to prevent cardiovascular disease. The WHI studies reported increased risk of deep vein thrombosis (DVT) and stroke with CE, and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) with CE with MPA in patients who are postmenopausal. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Manage risk factors appropriately; discontinue use immediately if adverse cardiovascular events occur or are suspected. Due to possible lower risk of thrombotic events, transdermal administration may be preferred for treating vasomotor symptoms of menopause in patients with risk factors for cardiovascular disease (AACE/ACE [Cobin 2017]; ACOG 556 2013; ES [Stuenkel 2015]). Edema requiring discontinuation of treatment and diuretic therapy may occur in patients with preexisting cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May impair glucose tolerance; use caution in patients with diabetes. Prior to therapy, consider age and cardiovascular and metabolic risk factors in patients previously diagnosed with diabetes (AACE/ACE [Cobin 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use caution with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Estrogens are poorly metabolized in patients with hepatic impairment. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic impairment occurs. Prolonged use of high doses of androgens has been associated with serious hepatic effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice). Edema requiring discontinuation of treatment and diuretic therapy may occur in patients with preexisting hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Use with caution in patients with severe hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution with migraine; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus: Use with caution in patients with systemic lupus erythematosus; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue estrogens at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Many warnings are based on data from the Women’s Health Initiative (WHI) studies that evaluated oral estrogen/progestin combinations (CE with or without MPA). Data related to use of estrogen/androgen combinations (esterified estrogens with methyltestosterone) from the WHI study are significantly less (Kabat 2014). In addition, products containing estrogens (esterified) and methyltestosterone have not received pre-market approval by the FDA. Information in this monograph has been expanded beyond the available prescribing information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risks vs benefits: When used for the relief of menopausal symptoms, the benefit-risk of hormone therapy is most favorable if started in patients who have no contraindications to therapy, are &lt;60 years of age, within 10 years of menopause onset, have a favorable lipid profile, and do not have the factor V Leiden genotype or metabolic syndrome. Risk factors for cardiovascular disease should also be considered when evaluating therapy and route of administration (AACE/ACE [Cobin 2017]; NAMS 2022). Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women’s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied. Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</p></div>
<div class="block foc drugH1Div" id="F167631"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Covaryx: Esterified estrogens 1.25 mg and methyltestosterone 2.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Covaryx HS: Esterified estrogen 0.625 mg and methyltestosterone 1.25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EEMT: Esterified estrogens 1.25 mg and methyltestosterone 2.5 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EEMT HS: Esterified estrogen 0.625 mg and methyltestosterone 1.25 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Est Estrogens-Methyltest DS: Esterified estrogens 1.25 mg and methyltestosterone 2.5 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Est Estrogens-Methyltest HS: Esterified estrogen 0.625 mg and methyltestosterone 1.25 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake, methylparaben, propylparaben, quinoline (d&amp;c yellow #10) aluminum lake, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Est Estrogens-Methyltest HS: Esterified estrogens 0.625 mg and methyltestosterone 1.25 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Est Estrogens-Methyltest HS: Esterified estrogens 0.625 mg and methyltestosterone 1.25 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Esterified estrogens 0.625 mg and methyltestosterone 1.25 mg [DSC], Esterified estrogens 1.25 mg and methyltestosterone 2.5 mg</p></div>
<div class="block geq drugH1Div" id="F167617"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F167637"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Covaryx HS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.625-1.25 mg (per each): $3.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Covaryx Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25-2.5 mg (per each): $3.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (EEMT HS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.625-1.25 mg (per each): $4.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (EEMT Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25-2.5 mg (per each): $4.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Est Estrogens-Methyltest Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25-2.5 mg (per each): $3.36 - $4.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F20748819"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-III or nonscheduled (DEA exemption status dependent)</p></div>
<div class="block hazard drugH1Div" id="F49104491"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F167632"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Vasomotor symptoms associated with menopause: </b>Treatment of moderate to severe vasomotor symptoms associated with menopause not improved by estrogens alone.</p></div>
<div class="block mst drugH1Div" id="F167658"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Covaryx HS may be confused with Covera HS</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappropriate medications to be avoided in postmenopausal patients ≥65 years of age (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection. Starting therapy in postmenopausal patients ≥60 years of age has greater risks (eg, heart disease, stroke, blood clots, dementia) than benefits. In postmenopausal patients already taking systemic estrogens, consider deprescribing (Beers Criteria [AGS 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">Methyltestosterone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years of age and older due to its potential for cardiac problems (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F167649"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F167625"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Androgens may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).  Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension-Associated Agents: May enhance the hypertensive effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F167638"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Estrogens should not be used during pregnancy. This product is specifically contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Estrogens (Esterified) monograph and the Testosterone monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F12708386"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">This product is specifically contraindicated in patients who are breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to the Estrogens (Esterified) monograph and the Testosterone monograph for additional information.</p></div>
<div class="block mop drugH1Div" id="F167629"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Prior to therapy, baseline risk for breast cancer and cardiovascular disease. During therapy, liver function tests; signs of virilization (eg, hirsutism, acne, deepening of voice, clitoromegaly); age appropriate breast and pelvic exams; blood pressure; unscheduled bleeding lasting &gt;6 months for endometrial pathology (sooner in patients who are obese, diabetic, or have a history of endometrial cancer); serum triglycerides (2 weeks after starting therapy in patients with baseline level &gt;200 mg/dL); TSH (6 to 12 weeks after starting oral therapy in patients taking thyroid replacement); efficacy beginning 1 to 3 months after starting therapy, then every 6 to 12 months as appropriate. Duration of treatment should be evaluated at least annually (ES [Stuenkel 2015]).</p></div>
<div class="block pha drugH1Div" id="F167620"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Conjugated estrogens: Activate estrogen receptors (DNA protein complex) located in estrogen-responsive tissues. Once activated, regulate transcription of certain genes leading to observed effects. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Testosterone: Increases synthesis of DNA, RNA, and various proteins in target tissues</p></div>
<div class="block phk drugH1Div" id="F167634"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Refer to the Estrogens (Esterified) and the Testosterone monographs.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F167640"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Covaryx | Covaryx HS | Eemt | Esterified estrogens and methyltestosterone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635705">
<a name="23635705"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <i>Obstet Gynecol</i>. 2013;121(4):887-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/23635705/pubmed" id="23635705" target="_blank">23635705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812486">
<a name="23812486"></a>American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 565: Hormone therapy and heart disease. <i>Obstet Gynecol</i>. 2013;121(6):1407-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/23812486/pubmed" id="23812486" target="_blank">23812486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15082697">
<a name="15082697"></a>Anderson GL, Limacher M, Assaf AR, et al, "Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial." <i>JAMA</i>, 2004, 291(14):1701-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/15082697/pubmed" id="15082697" target="_blank">15082697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Federal.1">
<a name="Federal.1"></a>"Certain Estrogen-Androgen Combination Drugs; Drugs for Human Use; Drug Efficacy Study Implementation; Amendment and Opportunity for Hearing," <i>Federal Register</i> 68(71):17953-57.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi: 10.4158/EP171828.PS.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Covaryx and Covaryx HS tablets (esterified estrogens and methyltestosterone) [prescribing information]. Boca Raton, FL: Centrix Pharmaceutical Inc; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28816933">
<a name="28816933"></a>Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i>. 2018;25(1):11-20. doi: 10.1097/GME.0000000000000956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/28816933/pubmed" id="28816933" target="_blank">28816933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581664">
<a name="20581664"></a>DeSancho MT, Dorff T, and Rand JH, "Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy," <i>Blood Coagul Fibrinolysis</i>, 2010, 21(6):534-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/20581664/pubmed" id="20581664" target="_blank">20581664</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Esterified estrogens and methyltestosterone tablets (prescribing information). Hauppauge, NY: Amneal Pharmaceuticals of NY; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193047">
<a name="22193047"></a>Goodman NF, Cobin RH, Ginzburg SB, et al; American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. <i>Endocr Pract</i>. 2011;17(suppl 6):1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/22193047/pubmed" id="22193047" target="_blank">22193047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16476878">
<a name="16476878"></a>Hsia J, Langer RD, Manson JE, et al, "Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative," <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/16476878/pubmed" id="16476878" target="_blank">16476878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25011395">
<a name="25011395"></a>Kabat GC, Kamensky V, Heo M, et al. Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women. <i>Maturitas</i>. 2014;79(1):70-76. doi: 10.1016/j.maturitas.2014.06.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/25011395/pubmed" id="25011395" target="_blank">25011395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16935599">
<a name="16935599"></a>Khurana RN, LaBree LD, Scott G, et al, "Esterified Estrogens Combined With Methyltestosterone Raise Intraocular Pressure In Postmenopausal Women," <i>Am J Ophthalmol</i>, 2006, 142(3):494-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/16935599/pubmed" id="16935599" target="_blank">16935599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35797481">
<a name="35797481"></a>North American Menopause Society (NAMS). Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/35797481/pubmed" id="35797481" target="_blank">35797481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14749144">
<a name="14749144"></a>Phillips EH, Ryan S, Ferrari R, et al, "Estratest And Estratest HS (Esterified Estrogens and Methyltestosterone) Therapy: A Summary of Safety Surveillance Data, January 1989 to August 2002," <i>Clin Ther</i>, 2003, 25(12):3027-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/14749144/pubmed" id="14749144" target="_blank">14749144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117397">
<a name="12117397"></a>Rossouw JE, Anderson GL, Prentice RL, et al, “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,”<i>JAMA</i>, 2002, 288(3):321-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/12117397/pubmed" id="12117397" target="_blank">12117397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771112">
<a name="12771112"></a>Shumaker SA, Legault C, Rapp SR, et al, “Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,” <i>JAMA</i>, 2003, 289(20):2651-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/12771112/pubmed" id="12771112" target="_blank">12771112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline [published online ahead of print October 7, 2015]. <i>J Clin Endocrinol Metab</i>. 2015:jc20152236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242325">
<a name="17242325"></a>Suthers K, "Estratest is Not Approved by the Food and Drug Administration," <i>Arch Intern Med</i>, 2007, 167(2):205-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/17242325/pubmed" id="17242325" target="_blank">17242325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16864758">
<a name="16864758"></a>Tamimi RM, Hankinson SE, Chen WY, et al, "Combined Estrogen And Testosterone Use And Risk Of Breast Cancer In Postmenopausal Women," <i>Arch Intern Med</i>, 2006, 166(14):1483-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/16864758/pubmed" id="16864758" target="_blank">16864758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>U.S. Food and Drug Administration, Department of Health and Human Services, “WHIMS Study on Estrogen/Progestin,” May 27, 2003. Available at <a href="http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21659542">
<a name="21659542"></a>van Vlijmen EF, Veeger NJ, Middeldorp S, et al, "Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception," <i>Blood</i>, 2011, 118(8):2055-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esterified-estrogen-and-methyltestosterone-drug-information/abstract-text/21659542/pubmed" id="21659542" target="_blank">21659542</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8740 Version 250.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
